TECHNOLOGY LICENSING OPPORTUNITY: NanoFET
Special Notice from Department of Energy.
Data as of Oct 24, 2026. Sources: SAM.gov and Grants.gov. Snapshot govcon-directory-20261024T104923Z-2151694.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services. Counts and totals are computed by DSE from public SAM.gov and Grants.gov notices. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Closing in 55 days
Notice details
- Agency
- Department of Energy
- Sub-tier agency
- ENERGY, DEPARTMENT OF
- Notice type
- Special Notice
- Solicitation number
- S-194657
- Product/service code
- AJ12
- Place of performance
- Los Alamos, New Mexico
- Posted
- Jun 18, 2026
- Response deadline
- Dec 18, 2026
- Source
- SAM.gov
Description
NanoFiber Engineered Therapeutics Platform (NanoFET) from Los Alamos National Laboratory offers pharmaceutical and biodefense organizations a modular, adaptable scaffold for building next-generation immunotherapies. By merging self-assembling peptide nanofibers with interchangeable nanobody and peptide components, the platform enables rapid development of targeted treatments that bridge disease agents directly to the patient�s own immune cells. Infectious diseases and chronic conditions such as cancer continue to impose enormous public health and economic burdens worldwide. Conventional vaccines and biologics are typically designed against a single pathogen or target, leaving populations vulnerable when new or unknown threats emerge. For military personnel and first responders, the absence of broad-spectrum medical countermeasures means that exposure to an unidentified pathogen in the field can be met with little more than supportive care. In cancer immunotherapy, connecting tumor cells to the patient�s own immune effector cells remains a formidable engineering challenge; current bispecific antibody formats are complex to manufacture, expensive and often limited in the number of targets they can engage simultaneously. Meanwhile, traditional antibody-based therapeutics are large molecules that can be difficult to produce at scale, may trigger unwanted immune reactions and lack the modularity needed for rapid adaptation to new disease targets. A platform capable of addressing
Summarized from the official notice. The description is shortened; read the full text on the official notice.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Similar open notices
- TIDAL: Target-Induced Droplet Assembly of LigandsClosing in 46 days
- TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterClosing in 53 days
- TECHNOLOGY LICENSING OPPORTUNITY: Protein-Based Rare Earth Recovery via CondensationClosing in 60 days
- TECHNOLOGY LICENSING OPPORTUNITY: SignalGenClosing in 149 days
Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →Frequently asked questions
When is the response deadline?
The published deadline is Dec 18, 2026. That is 55 days after the data date.
What NAICS code applies?
NAICS 541714, Research and Development in Biotechnology (except Nanobiotechnology).
Which agency issued this notice?
Department of Energy.
Where is the official notice?
The link under Official notice opens the source listing.